RBC Capital analyst Brian Abrahams maintained a Buy rating on Gilead Sciences (GILD - Research Report) on September 8 and set a price target of $79.00. The company's shares closed yesterday at $65.28.According to TipRanks, Abrahams is a 4-star analyst with an average return of 3.0% and a 47.17% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Regeneron, Gilead Sciences, and Biogen.Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $71.50, which is a 9.53% upside from current levels. In a report released on September 7, Mizuho Securities also maintained a Buy rating on the stock with a $75.
https://www.tipranks.com/news/blurbs/gilead-sciences-gild-gets-a-buy-from-rbc-capital?utm_source=advfn.com&utm_medium=referral
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Gilead Sciences Charts.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Gilead Sciences Charts.